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ABSTRACT 
Objective: The objective of this research was to formulate and evaluate iron oxide nanoparticles for treatment of iron deficiency anemia (IDA). 
Methods: Iron oxide nanoparticles were prepared by co-precipitation method and stabilized by coating with folic acid or chitosan. The prepared 
nanoparticles were characterized in vitro for morphology, particle size, zeta potential, crystallinity and ultraviolet-visible (UV-Vis) absorption. In 
vivo studies were performed to evaluate the efficacy of the prepared nanoparticles in treating iron-deficient anemic rats compared to the 
commercial iron product. 
Results: In vitro results revealed that particle sizes were 65.95±5 nm, 220.2±12 nm and 295.3±19 nm for uncoated iron oxide nanoparticles, folic 
acid-coated iron oxide nanoparticles and chitosan coated iron oxide nanoparticles, respectively. UV-Vis absorption spectrum and x-ray diffraction 
(XRD) patterns confirmed that the prepared nanoparticles were iron oxide nanoparticles. In vivo results indicated that folic acid-coated iron oxide 
nanoparticles showed effective restorative action, returning haemoglobin (Hb) concentration to normal levels, where not only complete recovery of 
Hb within short time from the anemic state to the high normal level, but also improved Hb concentrations compared to the commercial iron 
product. 
Conclusion: The results obtained in this research work clearly indicated a promising potential of folic acid-coated iron oxide nanoparticles for the 
effective treatment of IDA. 
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Iron deficiency anemia (IDA) is the most common nutritional 
disorder in which the capacity of blood to deliver oxygen to body 
cells and tissues is reduced [1-3]. It’s possible to have the symptoms 
for years without ever knowing the cause. A lot of people don’t know 
that they suffer from IDA. The diagnosis of IDA is confirmed by the 
findings of low iron stores and Hb level below normal. In women of 
childbearing age, loss of iron in the blood due to heavy 
menstruation, pregnancy, inadequate iron intake and decreased iron 
absorption are the most common causes of IDA [4]. 
Doctors normally treat the condition with iron supplements and 
changes in diet [5]. Ferric and ferrous iron salts are the most 
commonly used iron supplements such as ferrous sulfate, ferric 
citrate, ferrous gluconate and ferric sulfate [6]. Treatment of IDA 
with iron supplements may be limited as they are associated 
with gastrointestinal side effects such as constipation, nausea, 
abdominal discomfort and dark colored stool. Delayed-release 
and enteric-coated iron supplements have been developed to 
increase patient compliance as they cause fewer side effects; 
however, they are not as well absorbed as the non-enteric coated 
preparations [7]. 
Nanoparticles have emerged as a promising strategy for the efficient 
delivery of drugs [8-12]. Recent researches on the gastrointestinal 
absorption of nanoparticles focus on enhancing the absorption of 
drugs, vaccines and nutrients that either are degraded by the 
digestive process or poorly absorbed [13, 14]. Several iron 
nanoparticles formulations were prepared to treat IDA with great 
efficiency and low side effects instead of the frequently used iron 
salt [15, 16]. The objective of this study was to prepare iron oxide 
nanoparticles and evaluate their potential as an iron supplement in 
the treatment of IDA compared to a commercial iron preparation. 
MATERIALS AND METHODS  
Materials  
Ferric chloride (FeCl3, 6 H2O, 98 %) was purchased from Alpha 
chemicals, Mumbai, India. Ferrous sulphate (FeSo4, 7 H2
Preparation of iron oxide nanoparticles 
O) was 
purchased from nice chemicals Pvt. Ltd., Kerala, India. Ammonia 
solution (33%) and phosphoric acid were purchased from El Nasr 
pharmaceutical chemicals Company, Cairo, Egypt. Chitosan and folic 
acid were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Choline chloride, casein and DL-methionine were purchased from 
Loba chemie Pvt. Ltd., Mumbai, India. All chemicals were of 
analytical grade and were used without further purification. 
Iron oxide nanoparticles were prepared according to a previously 
reported method [17] with slight modifications. Briefly, 5 ml ferric 
chloride (0.25 M) was added to 5 ml ferrous sulfate (0.25 M) and 
mixed well. A magnetic stirrer was used for stirring the solution for 
20 min at 45 °C to remove any oxygen dissolved in the preparation. 
40 ml (1 M) Ammonia solution was added and the obtained mixture 
was stirred for a further 30 min until a precipitate was formed. The 
preparation was centrifuged for 8 min at 6000 rpm, and the 
precipitate was washed with deionized water. The washing 
procedure was repeated four times to remove any excess ammonia. 
The precipitate was directly dried in an oven at 60 °C for 24 h. 
Preparation of folic acid coated nanoparticles 
In an aqueous medium, iron oxide nanoparticles were prepared by 
mixing 5 ml ferric chloride (0.25 M) with 5 ml ferrous sulfate (0.25 M), 
and then the mixture was stirred constantly by a magnetic stirrer for 
30 min at 45 °C to remove any oxygen dissolved in the preparation. 
Folic acid (0.2 g) was dissolved in 40 ml Ammonia (1 M), and then 
added to the preparation. For a further 30 min, the mixture was 
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stirred constantly until a precipitate formed. The precipitate was 
separated by centrifugation and washed four times to remove excess 
ammonia, then dried in an oven at 60 °C for 24 h 
Preparation of chitosan-coated iron oxide nanoparticles 
The previously prepared uncoated iron oxide nanoparticles were 
mixed with 10 ml (0.2 mg/ml) chitosan. The pH was adjusted to 4.0 by 
adding a small amount of phosphoric acid, and then stirring was 
continued for 12 h by a magnetic stirrer. The prepared nanoparticles 
were separated by centrifugation and washed four times with 
deionized water. The precipitate was directly dried in an oven at 60 °C 
for 24 h. 
Morphology of iron oxide nanoparticles  
Morphological examination of iron oxide nanoparticles was carried 
out using transmission electron microscope (TEM), (Tecani-G20 
microscope, FEI, The Netherlands), equipped with super twin lens, a 
LaB6 electron source and operated at 60 kV. A droplet of iron oxide 
nanoparticles dispersion was placed on a carbon-coated copper grid, 
and the excess fluid was removed by an absorbent filter paper. The 
samples were viewed using magnification up to 1000000 x. 
Particle size and zeta potential determination 
Particle size, size distribution and zeta potential were measured 
by (Malvern Zetasizer nano, Worcestershire, UK). The samples 
were dispersed in deionized water followed by sonication for 5 
min, then the prepared nanoparticles were measured triplicates at 
room temperature using a 45 mm focus lens and a beam length of 
2.4 mm. 
X-ray diffraction study (XRD) 
XRD patterns of iron oxide nanoparticles were obtained using (X'Pert-
PRO Diffractometer, PAN alytical, Netherlands). The diffractograms 
were recorded at room temperature with Cu as tube anode, under the 
following conditions: steps were 0.02 ° of (°2θ), the counting rate was 
0.5s/step, the current was 30 mA, and the voltage was 45 kV. Data 
were collected using scattering angle (2θ) ranged from 4 ° to 80 °. 
Ultraviolet-visible spectroscopy (UV-Vis) 
Absorption spectrum of uncoated iron oxide nanoparticles was 
recorded using a spectrometer (Lambda EZ 201, Perkin Elmer, 
Massachusetts, USA) over the range of 200 to 600. 
In vivo evaluation of iron oxide nanoparticles in treatment of 
IDA 
This in vivo study was performed to evaluate the potential of iron 
oxide nanoparticles in the treatment of IDA in rats compared to a 
commercially available iron supplement product. This study 
approval was obtained from the Animal Ethics Committee of Faculty 
of Pharmacy, Helwan University (approval number: 005A-12). The 
ethics committee guidelines were followed during the study. Thirty-
two female Wistar rats (3 w old), weighing 100±10 g were used in 
the study. All rats were maintained in a temperature and light 
controlled room. Blood samples were withdrawn prior to induction 
of IDA from the retro-orbital sinus using heparinized glass capillary 
tubes. Blood samples were analyzed for hemoglobin (Hb) 
concentration using ABX animal cell counter, Montpellier, France.  
The rats were divided randomly into four groups, each of 8 rats. 
Group (A) was a control group, where rats were fed normal diet 
during the whole experimental period. The treatment groups (B, C 
and D) were fed iron free basal diet till becoming normal nutritional 
iron-deficient anemic rats. The anemic rats in each treatment group 
(B, C and D) were divided into two subgroups (4 rats each) treated 
with one daily dose of two different doses (2 mg/kg and 4 mg/kg) of 
commercially available iron supplement product containing ferrous 
sulfate, uncoated iron oxide nanoparticles and folic acid-coated iron 
oxide nanoparticles, respectively. The doses of all treatments were 
suspended in 1.0 % carboxymethylcellulose solution and given 
orally for 4 w with an animal feeding needle. At the end of treatment 
period, blood samples were collected in heparinized glass tubes and 
analyzed for Hb concentration. 
Preparation of iron-free basal diet 
Standard iron free basal diet was prepared from fine ingredients. 
The diet had the following composition per 100 g: Sunflower oil 
10%, salt mixture 4% [18], vitamin mixture1%, choline chloride 
0.2%, protein 12%, DL-methionine, and cornstarch up to 100 g [19].  
Statistical analysis 
Data are expressed as the menthe standard deviation. Paired t-test 
was used to analyze the obtained data and any P value less than 0.05 
was considered to be statistically significant. 
RESULTS AND DISCUSSION 
Morphology of iron oxide nanoparticles 
TEM images of the uncoated iron oxide nanoparticles (fig. 1A) 
showed spherically shaped particles with average diameter of 
8.33±1.64 nm which is in good agreement with previous research 
[16]. The folic acid coated (fig. 1B) and chitosan coated iron oxide 
nanoparticles (fig. 1C) were similar in shape but larger in size with 
aggregations. Similar results have been previously reported [15-17]. 
The observed aggregations of the coated iron oxide nanoparticles 
might be due to the incomplete coating of individual particles by 
folic acid or chitosan [20]. 
 
Fig. 1: TEM images of (A) uncoated iron oxide nanoparticles, (B) 
folic acid-coated iron oxide nanoparticles and (C) chitosan 
coated iron oxide nanoparticles 
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Particle size and zeta potential 
The mean particle size of uncoated iron oxide nanoparticles was 
65.95±5 nm which is in good agreement with previously reported 
results [17]. After coating with folic acid and chitosan, the mean 
particle size increased to 220.2±12 nm and 295.3±19 nm, 
respectively. The obtained particle sizes of the coated iron oxide 
nanoparticles are larger than that reported previously for either 
folic acid-coated [15] or chitosan-coated iron oxide nanoparticles 
[17]. The particle size distribution of all samples (fig. 2) showed 
unimodal patterns. The average zeta potential of the uncoated iron 
oxide nanoparticles, folic acid-coated iron oxide nanoparticles and 
chitosan coated iron oxide nanoparticles were-25.6±3 mV,-10.9±1.9 
mV and-0.668±0.1 mV, respectively. Similar results were reported 
previously [17]. The zeta potentials of chitosan-coated iron oxide 
nanoparticles and folic acid-coated iron oxide nanoparticles are 
higher than that of uncoated iron oxide nanoparticles due to the 
highly positive charge of chitosan and folic acid [21]. 
 
 
Fig. 2: Particle size distribution curve of the prepared iron oxide nanoparticles 
 
XRD analysis  
XRD patterns of the prepared iron oxide nanoparticles showed the 
six characteristic peaks of iron oxide at 2θ values of 30.1, 35.5, 43.3, 
53.7, 57 and 62.8 (fig. 3). Similar results have been previously 
reported [22]. Peaks assigned to chitosan (2θ = 8 ° and 20 °), and 
peaks assigned to folic acid (2θ =10.2 °, 12.7 °and 26.6 °) were still 
observed after coating which is similar to previously reported 
results [23, 24]. Sharp peaks also suggest that the iron oxide 
nanoparticles have good crystallized structure. Peak widening was 
consistent with the small particles sizes of the nanoparticles [25]. 
 
 
Fig. 3: XRD patterns of (A) uncoated iron oxide nanoparticles, 
(B) folic acid-coated iron oxide nanoparticles and (c) chitosan 
coated iron oxide nanoparticles 
 
UV-Vis absorption spectroscope 
The observed UV band (fig. 4) originated primarily from the 
absorption and scattering of light by iron oxide nanoparticles. The 
high absorption band of iron oxide nanoparticles at 340 nm is in 
good agreement with previous literature [26]. 
 
Fig. 4: UV-Vis absorption spectrum of uncoated iron oxide 
nanoparticles 
 
In vivo evaluation of iron oxide nanoparticles in treatment of IDA 
Induction of anemia in rats 
No animal mortality was found in rats during IDA induction period, 
but some symptoms such as loss of appetite were observed. The 
effect of iron free diet on Hb concentration in rats after 6 w of 
feeding was shown in table (1).  
The mean Hb concentration was reduced by 63% compared to 
control rats which suggest successful induction of IDA among the 
three groups of rats. Similar results have been previously reported 
[15, 16]. 
Treatment of IDA in rats 
The mean percentage increase in Hb concentrations in anemic rats 
were 118.95%, 163% and 294.5% after 4 w treatment with 2 mg/ml 
of commercial iron product, uncoated iron oxide nanoparticles and 
folic acid-coated iron oxide nanoparticles, respectively. The mean 
percentage increase in Hb concentrations in anemic rats were 
178.87%, 206% and 297.02% after 4 w treatment with 4 mg/ml of 
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commercial iron product, uncoated iron oxide nanoparticles and 
folic acid-coated iron oxide nanoparticles, respectively.  
All treatment groups (group B, C and D) showed significant 
(P<0.05, paired t-test) increase in Hb concentrations in both 
two doses (2 mg/kg and 4 mg/kg) relative to the mean 
baseline blood Hb after induction of anemia as shown in table 
(2) and (3).  
Similar results have been previously reported [15]. 
 
Table 1: Effect of iron-free basal diet on blood Hb concentrations in rats after 6 w 
 Week Mean blood hemoglobin (g/dl±SD, n=8) 
Group (B) Group (C) Group (D) Average 
0 12.5±1.1 12.7±0.9 11.9±1.5 12.4±1.2 
6 4.59±0.59 5±0.57 4.03±0.04 4.54±0.4 
Data are given in mean±SD, dl= deciliter, SD= standard deviation, n= number of rats. 
 
The higher efficacy of iron oxide nanoparticles relative to 
commercial iron supplement product can be explained by the 
enhanced bioavailability and therapeutic effectiveness of iron by 
increasing the surface area. Recent researchers have demonstrated 
that nanonization of poorly absorbed drugs can improve cellular 
uptake and oral bioavailability of these drugs [27, 28]. The increased 
efficacy of folic acid-coated iron oxide nanoparticles relative to 
uncoated iron oxide nanoparticles could be explained that coating 
prevents aggregation of nanoparticles which increases stability and 
enhances absorption [29]. 
 
Table 2: Mean blood Hb concentrations before and after 4 w of treatment with a dose of 2 mg/kg 
Group of rats Mean blood hemoglobin concentration (g/dl±SD, n=4) 
Before treatment After 4 w treatment 
Commercial iron product (B1) 4.59±0.59 10.05±1.5 
Uncoated iron oxide nanoparticles (C1) 5±0.57 13.15±0.5 
Folic acid coated iron oxide nanoparticles (D1) 4.03±0.04 15.9±0.57 
Data are given in mean±SD, dl= deciliter, SD= standard deviation, n= number of rats. 
 
Table 3: Mean blood Hb concentrations before and after 4 w of treatment with a dose of 4 mg/kg 
Group of rats Mean blood hemoglobin concentration (g/dl±SD, n=4) 
Before treatment After 4 w treatment 
Commercial iron product (B2) 4.59±0.59 12.8±0.99 
Uncoated iron oxide nanoparticles (C2) 5±0.57 15.3±0.57 
Folic acid-coated iron oxide nanoparticles (D2) 4.03±0.04 16±0.71 
Data are given in mean±SD, dl= deciliter, SD= standard deviation, n= number of rats. 
 
CONCLUSION 
Based on the previous results, iron oxide nanoparticles were 
successfully synthesized and coated with chitosan and folic acid. The 
synthesized nanoparticles were spherical shaped particles with a 
mean size in the range of 65.95±5 to 295.3±19. In vivo results 
indicated that iron oxide nanoparticles achieved great success in 
treating IDA in the experimental animal model, achieving complete 
recovery of anemic rats from the anemic state to a normal Hb level 
within short time. The investigation clearly indicated a promising 
potential of iron oxide nanoparticles as an iron supplement for the 
effective treatment of IDA.  
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